What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It?

The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 500 over its track record. Analysts suggest more diversified alternatives like the Vanguard International High Dividend Yield ETF (VYMI) may be better for long-term investors.

07/09/2026, 11:05 AM • The Motley Fool

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Despite expanding biologic adoption and evolving treatment strategies for systemic lupus erythematosus (SLE), research from Spherix Global Insights reveals substantial unmet need remains. While rheumatologists are advancing treatment strategies and increasing biologic utilization, nearly 80% of patients report moderate-to-severe disease with persistent symptoms and frequent flares. Approximately one-third of biologic-treated patients achieve only partial disease control. Recent approvals like Saphnelo® (anifrolumab) and anticipated approvals like Gazyva® (obinutuzumab) for non-renal SLE are expected to expand treatment options.

07/07/2026, 12:58 PM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Pharmaceutical Regulatory Affairs in Asia: Three-Day Online Course Opens Registration for October 20–22, 2026 Early-Bird Pricing Ends September 15

ResearchAndMarkets.com is launching a three-day online training course on pharmaceutical regulatory affairs in Asia (October 20-22, 2026) designed to help regulatory professionals navigate the region's complex and diverse compliance landscape. The course covers nine major Asian markets including China, India, Korea, and ASEAN countries, with instruction from experienced industry experts Alan Chalmers and Monica Dressler-Meyer. Early-bird pricing ends September 15, 2026.

07/06/2026, 10:55 AM • GlobeNewswire

Geopolitical Tensions Impacting AI in Pathology Market: Insights into US-Israel-Iran Conflicts on Market Dynamics

The global AI in Pathology market is valued at USD 28.75 Million in 2025 and expected to reach USD 68.81 Million by 2035 with a 9.12% CAGR. However, the US-Israel-Iran conflict is creating headwinds, causing IDC to revise US IT spending growth downward and disrupting cloud infrastructure and semiconductor supply chains. Despite challenges, AI infrastructure investment remains strong as enterprises seek automation solutions.

07/03/2026, 7:59 AM • GlobeNewswire

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market share. Key challenges include metabolic pathway complexity and cancer cell plasticity, while strategic collaborations are accelerating development.

07/03/2026, 7:54 AM • GlobeNewswire

Molecular Biology Enzymes, Reagents and Kits Market Size Worth USD 70.85 Billion by 2035 | SNS Insider

The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.

07/03/2026, 6:48 AM • GlobeNewswire

Unlocking Growth in the Sweden Flu Market: The Rise of Molecular Diagnostics and Targeted Antiviral Therapies

Sweden's flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031 at a 4.1% CAGR, driven by high influenza burden among elderly populations and increased adoption of molecular diagnostics and targeted antiviral therapies. The market operates within Sweden's centralized healthcare system with key players including Roche, Thermo Fisher Scientific, 3M, and Meridian Bioscience, though growth is constrained by seasonality, regulatory compliance requirements, and supply chain vulnerabilities.

07/03/2026, 4:47 AM • GlobeNewswire

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.

07/02/2026, 6:33 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

RBC analyst Trung Huynh declared Eli Lilly the 'clear winner' at the American Diabetes Association conference, citing positive trial data for retatrutide and Foundayo. However, Novo Nordisk's chief science officer Martin Holst Lange argues the competition is far from over, noting that tolerability and effectiveness against comorbidities will play important roles. Eli Lilly reported 56% revenue growth last quarter, while Novo Nordisk experienced negative adjusted sales growth, creating a significant valuation gap between the two companies.

06/25/2026, 11:18 AM • The Motley Fool

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

06/19/2026, 5:39 AM • GlobeNewswire

Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

More than 100 prominent organizations have united to promote World Blood Donor Day on June 14, 2026, and Blood Advocacy Week (June 8-12). The initiative highlights that while blood transfusions are needed every 2 seconds in America, less than 3% of eligible Americans donate blood. The campaign theme is 'One Drop of Humanity. Give Blood. Save Lives.' emphasizing the critical need for volunteer blood donors.

06/14/2026, 8:54 AM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Nxera Pharma has joined OpenFold, a non-profit AI research consortium for drug discovery, alongside major pharmaceutical and technology companies including Bristol Myers Squibb, Novo Nordisk, Bayer, Roche, AWS, Microsoft, and NVIDIA. The participation aligns with Nxera's strategy to enhance R&D productivity through AI technologies and leverage its NxWave™ GPCR drug discovery platform with open-source structural prediction models.

06/10/2026, 2:35 AM • GlobeNewswire